Thyrocare Technologies (539871) Aperçu de l'action
Thyrocare Technologies Limited fournit des services de diagnostic aux patients, aux laboratoires et aux hôpitaux en Inde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 1/6 |
| Croissance future | 5/6 |
| Performances passées | 5/6 |
| Santé financière | 5/6 |
| Dividendes | 4/6 |
539871 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Thyrocare Technologies Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹567.20 |
| Plus haut sur 52 semaines | ₹662.00 |
| Plus bas sur 52 semaines | ₹342.55 |
| Bêta | 0.46 |
| Variation sur 1 mois | 0.94% |
| Variation sur 3 mois | 21.63% |
| Variation sur 1 an | 26.88% |
| Variation sur 3 ans | 212.28% |
| Variation sur 5 ans | 36.83% |
| Évolution depuis l'introduction en bourse | 175.34% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 15
539871: Fair Outlook As Objects Clause Change And Governance Steps Will Support Confidence
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹603 to ₹663, as they factor in slightly higher revenue growth assumptions, a marginally lower discount rate, a similar profit margin outlook, and a higher future P/E multiple in their updated model. What's in the News for Thyrocare Technologies Thyrocare Technologies has scheduled a board meeting on Jul 23, 2026 at 14:45 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026, along with the limited review report.Mise à jour du récit • Jun 19
539871: Expanded Healthcare Objects Clause And New Auditors Will Support Bullish View
Analysts have nudged their fair value estimate for Thyrocare Technologies slightly higher, from ₹600 to ₹603, reflecting updated assumptions around long term profit margins and future P/E expectations. What’s in the News for Thyrocare Technologies A board meeting is scheduled for May 07, 2026 to review and approve the audited standalone and consolidated financial results for the year ended March 31, 2026, and to consider several governance and audit related items (source: Key Developments).Recent updates
Mise à jour du récit • Aug 15
539871: Fair Outlook As Objects Clause Change And Governance Steps Will Support Confidence
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹603 to ₹663, as they factor in slightly higher revenue growth assumptions, a marginally lower discount rate, a similar profit margin outlook, and a higher future P/E multiple in their updated model. What's in the News for Thyrocare Technologies Thyrocare Technologies has scheduled a board meeting on Jul 23, 2026 at 14:45 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026, along with the limited review report.Mise à jour du récit • Jun 19
539871: Expanded Healthcare Objects Clause And New Auditors Will Support Bullish View
Analysts have nudged their fair value estimate for Thyrocare Technologies slightly higher, from ₹600 to ₹603, reflecting updated assumptions around long term profit margins and future P/E expectations. What’s in the News for Thyrocare Technologies A board meeting is scheduled for May 07, 2026 to review and approve the audited standalone and consolidated financial results for the year ended March 31, 2026, and to consider several governance and audit related items (source: Key Developments).Mise à jour du récit • Jun 04
539871: Expanded Healthcare Objects Clause Will Support Bullish Medium Term View
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹600, with unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. This indicates that the latest review did not alter their fundamental valuation framework for the stock.Mise à jour du récit • May 18
539871: Expanded Healthcare Mandate Will Support Bullish Medium Term View
Analysts have lifted their price target on Thyrocare Technologies from ₹571.67 to ₹600.00, and point to updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple as key drivers of the change. What's in the News The Board has approved changes to the Memorandum of Association to align it with the Companies Act, 2013, including updated references and clauses linked to current regulations (Key Developments).Mise à jour du récit • Apr 28
539871: Stable Return Assumptions Will Support Bullish Medium Term View
Analysts have kept Thyrocare Technologies' fair value estimate steady at ₹571.67 per share, with only small tweaks to inputs such as expected revenue growth, profit margin, and future P/E assumptions driving this unchanged price target. Valuation Changes Fair Value: Kept unchanged at ₹571.67 per share, indicating no net impact from the latest input updates.Mise à jour du récit • Apr 09
539871: Stable Assumptions And Upcoming Results Will Support Bullish View
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E in their latest update. What's in the News A board meeting is scheduled on January 28, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Mise à jour du récit • Mar 25
539871: Stable Assumptions And Upcoming Results Will Support Bullish Outlook
Analysts have kept their price target for Thyrocare Technologies broadly unchanged at around ₹572. This reflects stable assumptions on discount rate, revenue growth, profit margin and future P/E in their valuation work.Mise à jour du récit • Mar 11
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting largely unchanged views on fair value, discount rate, growth and profit assumptions. What's in the News Board meeting scheduled for January 28, 2026, to review and consider the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Mise à jour du récit • Feb 24
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margins and future P/E in their updated work. What's in the News A board meeting is scheduled for January 28, 2026, to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Mise à jour du récit • Feb 10
539871: Capitalisation Flexibility And Updated Profit Assumptions Will Support Returns
Analysts have slightly revised their price target on Thyrocare Technologies to ₹571.67, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that are now modestly lower than previously assumed. What's in the News Board meeting scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Mise à jour du récit • Jan 26
539871: Capitalisation Flexibility And Higher Future P/E Will Support Returns
Analysts have nudged their fair value estimate for Thyrocare Technologies higher from ₹560.56 to ₹571.67, reflecting updated views on its long term revenue growth, profit margins and future P/E assumptions. What's in the News A board meeting is scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Mise à jour du récit • Jan 10
539871: Stock Split And Bonus Share Flexibility Will Support Future Returns
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹506.67 to ₹560.56, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board approval has been sought via a postal ballot dated October 14, 2025 to increase authorised share capital to INR 3,000,000,000, split into 300,000,000 equity shares of INR 10 each, with related changes to the Memorandum and Articles of Association (company filing).Mise à jour du récit • Dec 26
539871: Stock Split And Bonus Capacity Will Drive Future Shareholder Returns
Analysts have maintained their price target for Thyrocare Technologies at ₹506.67 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News The board approved a proposal to increase authorised share capital and amend the Memorandum of Association and Articles of Association, subject to shareholder approval (Board Meeting, October 14, 2025, Key Developments).Mise à jour du récit • Dec 11
539871: Bonus Share And Stock Split Plan Will Drive Future Shareholder Value
Analysts have sharply reduced their price target on Thyrocare Technologies to approximately ₹507 from about ₹1,520. This reflects a recalibrated fair value framework even as underlying assumptions for growth, margins, discount rate and future valuation multiples remain largely unchanged.Mise à jour du récit • Nov 27
539871: Upcoming Board Approvals And Dividend Proposals Will Shape Shareholder Value
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹1,520 per share, citing stable outlooks in revenue growth and profit margins as the key drivers behind the unchanged price target. What's in the News The board meeting on October 14, 2025 considered and approved unaudited financial results for the quarter and half year ended September 30, 2025.Mise à jour du récit • Nov 12
539871: Upcoming Board Decisions And Shareholder Actions Will Influence Outlook
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable expectations for revenue growth, profit margin, and valuation metrics. What's in the News Special or Extraordinary Shareholders Meeting scheduled for November 16, 2025, to be conducted via postal ballot in India (Key Developments).Mise à jour du récit • Oct 29
Upcoming Bonus Shares And Dividend Proposal Will Drive Shareholder Value
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable revenue growth projections along with only minor adjustments in profit margin and future valuation metrics. What's in the News The board meeting was held on October 14, 2025 to approve unaudited financial results, consider the declaration of an interim dividend, and review a proposal for the issue of bonus shares (Board Meeting).Mise à jour du récit • Oct 15
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
Analysts have raised their fair value estimate for Thyrocare Technologies from ₹1,355 to ₹1,520. They cite improved profit margins and expectations of sustainable earnings, even though revenue growth is moderating.Mise à jour du récit • Sep 05
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
With both Net Profit Margin and Future P/E ratio remaining stable, analysts have kept Thyrocare Technologies’ fair value unchanged at ₹1355. What's in the News Special/Extraordinary Shareholders Meeting scheduled via postal ballot in India.
Nouveau récit • Jan 26
Integrating Vimta Labs And Achieving 100% NABL Accreditation Will Position The Company As An Industry Leader
Expanding geographical presence and strategic acquisitions are expected to drive future revenue growth and enhance service offerings.Rendement pour les actionnaires
| 539871 | IN Healthcare | IN Marché | |
|---|---|---|---|
| 7D | -6.5% | 0.5% | -1.0% |
| 1Y | 26.9% | 1.2% | 1.2% |
Rendement vs Industrie: 539871 a dépassé le secteur Indian Healthcare qui a rapporté 1.2 % au cours de l'année écoulée.
Rendement vs marché: 539871 a dépassé le marché Indian qui a rapporté 1.2 % au cours de l'année écoulée.
Volatilité des prix
| 539871 volatility | |
|---|---|
| 539871 Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Cours de l'action stable: 539871 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de 539871 ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1996 | 1,906 | Rahul Guha | www.thyrocare.com |
Thyrocare Technologies Limited fournit des services de diagnostic aux patients, aux laboratoires et aux hôpitaux en Inde. Son activité s'articule autour de trois segments : Services de tests de diagnostic, Services d'imagerie et Autres. L'entreprise propose divers tests de diagnostic médical et profils de tests axés sur la détection précoce et la gestion des troubles et maladies, notamment la thyroïde, la croissance, le métabolisme, l'auto-immunité, le diabète, l'anémie, les maladies cardiovasculaires, l'infertilité et diverses maladies infectieuses.
Thyrocare Technologies Limited Résumé des fondamentaux
| 539871 statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹92.63b |
| Bénéfices(TTM) | ₹1.76b |
| Recettes(TTM) | ₹8.76b |
51.2x
Ratio P/E10.3x
Ratio P/SLe site 539871 est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| 539871 compte de résultat (TTM) | |
|---|---|
| Recettes | ₹8.76b |
| Coût des recettes | ₹3.95b |
| Marge brute | ₹4.82b |
| Autres dépenses | ₹3.05b |
| Les revenus | ₹1.76b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 11.08 |
| Marge brute | 54.96% |
| Marge bénéficiaire nette | 20.12% |
| Ratio dettes/capitaux propres | 8.6% |
Quelles ont été les performances à long terme de 539871?
Voir les performances historiques et les comparaisonsDividendes
1.6%
Rendement actuel des dividendes91%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/20 13:12 |
| Cours de l'action en fin de journée | 2026/08/20 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Thyrocare Technologies Limited est couverte par 13 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Hrishikesh Patole | 360 ONE Capital Market Private Limited |
| Rahul Agarwal | CGS International |